G-CSF mobilized CD34+ cell transplantation as regenerative medicine for patients with spinal cord injuries. - CD34+ cell transplantation for spinal cord injuries.

Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Tokushukai Medical Group.0 个研究点目标入组 6 人开始时间: 2019年7月17日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 6

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 15years-old 至 70years-old（—）
性别: All

入选标准

未提供

排除标准

•1) Transection of the spinal cord with the MRI 2) Spinal shock 3) Central spinal cord injury 4) Organ failure more than SOFA scale 3 5) Disturbance of consciousness (Japan Come Scale (JCS) III-200 or III-300) 6) Severe respiratory disorder 7) Hematologic disease (leukemia, myeloproliferative disorders, myelodysplastic syndromes, or sickle cell disease) 8) Autoimmune disorders 9) Liver cirrhosis 10) Interstitial pneumonitis or history 11) Malignancy or history of malignancy most recently 12) Positive for following viral infectious disease, HBV, HCV, HIV, ATL, Parvovirus B19. 13) White blood cell count, under 2,000/micro L or greater than 15,000/micro L 14) Platelet count, under 100,000/micro L 15) Hemoglobin concentration, under 8 g/dL 16) Aspartate aminotransferase (GOT) or alanine aminotransferase (GPT), three times greater than normal value 17) Serum albumin, under 2 g/dL 18) Splenomegaly on computed tomography 19) Allergic reaction or adverse reaction to G-CSF, the other reagents, or apheresis 20) Allergic reaction or adverse reaction to the mouse-derived protein 21) Severe multiple injury or multiple organ failure 22) Hemophilia 23) Uncontrolled ischemic heart disease including receiving a cardiovascular surgery or percutaneous coronary intervention within 12 months; severe spinal and peripheral nerve disease; tetraplegia due to brain disorder (brain injury, cerebral infarction, etc.); renal dysfunction (hemodialysis, etc.); or severe psychiatric disorders 24) Pregnancy 25) Participating in other clinical studies within 6 months 26) Ineligible patients on this clinical study based on other clinical evidence

研究者

发起方

Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Tokushukai Medical Group.

相似试验

已完成

不适用

G-CSF mobilized CD34+ cell transplantation as regenerative medicine for patients with critical limb ischemia.Critical limb ischemia in patients undergoing hemodialysis

JPRN-UMIN000037339Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Tokushukai Medical Group.1

招募中

1 期

CD34+ cell transplantation for patients with acute renal failure.

JPRN-jRCTb030190231OHTAKE Takayasu9

招募中

2 期

CD34+ cell transplantation for patients with spinal cord injuries.Spinal cord injury

JPRN-jRCTb030190220WATANABE Tsuyoshi6

招募中

2 期

CD34+ cell transplantation for patients with CLI.

JPRN-jRCTb030190142OHTAKE Takayasu20

已完成

1 期

G-CSF mobilized CD34+ cell transplantation for hemodialysis patients with critical limb ischemia.peripheral arterial disease (critical limb ischemia)

JPRN-UMIN000015266Shonan Kamakura General Hospital10